Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days

Trial Details

NCT ID
NCT06717958
Phase
PHASE2
Sponsor
Technische Universität Dresden
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Ivosidenib 250 MG (milligram)
Locations (sample)
  • Aachen, Germany|50.77664,6.08342
  • Chemnitz, Germany|50.8357,12.92922
  • Dresden, Germany|51.05089,13.73832
  • Erlangen, Germany|49.59099,11.00783
  • Essen, Germany|51.45657,7.01228

Key Eligibility Criteria

  • AML or MDS with IDH1 mutation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →